Dyskeratosis congenita with leukoplakia: The differential diagnosis to consider and multidisciplinary management

Lauren Magnani, Danilo C. Delcampo, Marian Russo

ABSTRACT

Introduction: Dyskeratosis congenita (DC) is a rare genetic condition with a multitude of implications in all organ systems, including bone marrow failure, lung disease, and malignancies. The syndrome is marked by a classic triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. Patients are at increased risk of squamous cell carcinoma and hematolymphoid neoplasms. Clinicians need to pursue multidisciplinary management for this rare condition.

Case Report: We hereby present a case of an eight-year-old girl with dyskeratosis congenita with leukoplakia, nail dystrophy, and skin hyperpigmentation.

Conclusion: Herein, we report a case of presumed sporadic mutation for DC in a patient with leukoplakia on lingual surface with no family history of similar condition. In such rare genetic conditions, case reports are crucial in expanding the knowledge base pertaining to DC. Multidisciplinary healthcare is paramount to treating this condition.
Dyskeratosis congenita with leukoplakia: The differential diagnosis to consider and multidisciplinary management

Lauren Magnani, Danilo C. Delcampo, Marian Russo

ABSTRACT

Introduction: Dyskeratosis congenita (DC) is a rare genetic condition with a multitude of implications in all organ systems, including bone marrow failure, lung disease, and malignancies. The syndrome is marked by a classic triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. Patients are at increased risk of squamous cell carcinoma and hematolymphoid neoplasms. Clinicians need to pursue multidisciplinary management for this rare condition. Case Report: We hereby present a case of an eight-year-old girl with dyskeratosis congenita with leukoplakia, nail dystrophy, and skin hyperpigmentation. Conclusion: Herein, we report a case of presumed sporadic mutation for DC in a patient with leukoplakia on lingual surface with no family history of similar condition. In such rare genetic conditions, case reports are crucial in expanding the knowledge base pertaining to DC. Multidisciplinary healthcare is paramount to treating this condition.

INTRODUCTION

Dyskeratosis congenita (DC) is a genetic condition with a multitude of implications in all organ systems, including bone marrow failure, lung disease, and malignancies. Dyskeratosis congenita (DC) has an annual incidence of less than one per million. It is a progressive, genetic condition that escapes prompt diagnosis due to slow onset of clinical features in early youth. The pathogenesis involves defective telomere maintenance, and can be inherited in X-linked, autosomal dominant, or autosomal recessive pattern [1]. However, case reports note sporadic mutations in unidentified genes [1]. Mutations in at least ten telomere- and telomerase-associated genes have been described, but no targeted therapies are currently available.

The syndrome is marked by a classic triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. Patients are at increased risk of squamous cell carcinoma and hematolymphoid neoplasms. Patients usually...
succumb to complications related to deficient renewing capability of hematopoietic stem cells. Allogeneic hematopoietic stem cell transplantation is the only curative treatment currently available, though morbidity and mortality from transplantation remains high. This condition prompts the importance for multidisciplinary management and ongoing investigation.

Herein, we report a case of presumed sporadic mutation for DC in a patient with leukoplakia on lingual surface with no family history of similar condition. In such rare genetic conditions, case reports are crucial in expanding the knowledge base pertaining to DC. We aim to highlight the importance of various laboratory testing, clinical monitoring and the multidisciplinary nature of ongoing management.

CASE REPORT

At the age of three, the patient was noted by pediatrician to have new onset fingernail changes. She was otherwise healthy without noted medical problems. By the age of 6 years old, she developed bilateral toenail onychodystrophy and notable hyperpigmentation on the bilateral anterior shins. The patient’s mother stated that the above changes became more significant with each preceding year. She was then referred to dermatology for ongoing investigation.

Upon initial presentation to clinic at age seven-years-old, the patient was noted to have scattered reticulate hyperpigmented patches on the trunk and anterior lower extremities (Figure 1A). Further examination noted abnormal dentition with rudimentary conical teeth and an area of lingual leukoplakia with a white nodule on right lateral tongue (Figure 1B). Exam of extremities was notable for extensive onychodystrophy of the bilateral hands and feet (Figure 1C). Complete review of systems was otherwise negative, including no changes in eyesight, no gastrointestinal distress, and no shortness of breath. The patient has no other medical history and takes no medications. She has no family history of cancer, skin conditions, or any other contributory illnesses. Parents state they have no other children and have no similar skin changes in any known family members.

The parents agreed to a skin biopsy for histopathological confirmation. The patient tolerated a punch biopsy of anterior thigh which revealed classic histopathologic features of DC, including epidermal atrophy, telangiectasia of the superficial blood vessels, liquefaction degeneration of basal cells, and increased papillary dermal melanophages (Figure 2).

For concern with a genetic syndrome, further investigation was made into laboratory studies. To evaluate and monitor bone marrow status and cell blood lines, multiple blood tests were obtained including a complete blood count and telomere length testing. Her CBC was within normal limits. Further genetic laboratory testing reported an abnormally low telomere length, which is consistent with DC. Genetic mutations in DC affect telomerase components or telomere-stabilizing components that alter the renewing capabilities of hematopoietic stem cells. This results in very short telomeres that are responsible for genetic instability and predisposition to malignancy [1]. Due to financial constraints, specific gene sequencing and specific inheritance pattern was not obtained. Hence, a sporadic mutation can only be assumed in light of no other affected family members. Patient and family are considering further genetic testing in the future.

DISCUSSION

Currently, dyskeratosis congenita remains a difficult genetic condition without readily accessible curative
treatment besides bone marrow transplantation. Bone marrow failure (BMF) is a major cause of morbidity and mortality in DC patients in which 80% of patients develop pancytopenia before age twenty, of which half are before age ten [2]. Patients must have coordinated care and be closely followed by different specialists and pediatrics.

The classical triad associated with DC includes abnormal skin pigmentation, nail dystrophy and oral leukoplakia. However, this triad is not observed in every clinical setting and the time of onset for these medical problems varies among individuals. Therefore, the manifestations of DC do not progress in a predictable pattern [3]. Clinical manifestations often first appear in childhood. In general, abnormal skin and nail changes appear before age 10-years-old and BMF often occurs before age 20, with 90% of patients showing signs of failure before age 30-years-old. BMF is the principal cause of premature mortality [3].

Dyskeratosis congenita (DC) is inherited either by X-linked, autosomal dominant, or autosomal recessive pattern. Ten genes have been identified X-linked DKC1 is the most frequent mutation, occurring in approximately 40% of patients [1]. It encodes the nucleolar protein dyskerin, which is involved in telomere maintenance and ribosomal biogenesis. All mutations affect telomerase components or telomere-stabilizing components that result in very short telomeres. This alters the enzyme’s normal function, and results in defective renewing capabilities of hematopoietic stem cells.

Multidisciplinary management is critical for these patients for both screening and treatment of associated medical conditions (Table 1). Ophthalmology consultation is important as per DC patients are at risk for conjunctivitis, retinopathy, blepharitides, pterygium, and epiphora due to lacrimal duct stenosis. Ophthalmologic complications occur in half of DC patients, with epiphora being the most common [1]. Our patient was seen by ophthalmology and thus far has normal eye examinations.

Oral maxillary facial surgery consultation needs to be pursued since DC patients have an increased prevalence and severity of periodontal disease, as evidenced by our patient who has several abnormal teeth at the age of eight. In addition to the classic oral leukoplakia, DC patients have a higher incidence of buccal mucosa hyperpigmentation, hypocalcified teeth, and taurodontism [2]. Early childhood caries and other dental abnormalities are thought to be due to anomalies within structures of ectodermal origin, resulting in defects of the enamel organ or its epithelial attachment [4]. Leukoplakia carries risk of degeneration into squamous cell carcinoma, with 30% progressing to squamous cell carcinoma in 10–30 years [1]. Leukoplakia occurs in almost 90% of patients, most commonly first manifesting between ages 5 and 14 years old. Recurrent ulceration and erythroplakia occurs between ages 14 and 20-years-old. Erosive leukoplakia leading to carcinoma later develops in patients ages 20–30 [5]. This patient was evaluated by oral surgery within two months of initial presentation to dermatology. Parents declined immediate biopsy of lesion and patient will be closely monitored with oral surgeon for any changes into potential malignant transformation.

Pulmonary consultation is another multidisciplinary management for DC patients. Pulmonary fibrosis is one of the potential complications of DC that develops in up to 20% of patients [1]. It is thought to be due to cell apoptosis resulting from critically short telomeres in rapidly dividing lung cells [1]. Therefore, patients require routine close pulmonary follow-up with pulmonary function testing and chest X-rays to monitor for lung disease development. Pulmonary function testing was performed on this patient and the results were normal at that time, with no indication of restrictive lung disease.

Surveillance should include annual CBC if normal, and more frequent CBC if abnormalities are detected. One can also consider annual bone marrow aspirate and biopsy. Monthly self-examination for oral, head, and neck cancers are advised. Annual cancer screening by an otolaryngologist and dermatologist should be performed, as should annual gynecologic examination. Additionally, annual pulmonary function tests starting either at diagnosis or when the patient can perform the test (often around age eight years old). Routine dental screening every six months to yearly and good oral hygiene are recommended [3].

Table 1: Summary of multidisciplinary management and monitoring

| Medical Specialist to consider | Conditions to monitor | Labs/Procedures with frequency |
|--------------------------------|-----------------------|-------------------------------|
| Ophthalmology Clinic          | Conjunctivitis, retinopathy, blepharitis, pterygium, epiphora from lacrimal duct stenosis | Yearly exam |
| Ear/Nose/Throat and Oral Maxillary Facial Surgery Clinic | Oral leukoplakia, oral squamous cell carcinoma, buccal hyperpigmentation, hypocalcified dentition, taurodontism | Every six months to yearly exam |
| Pulmonary Clinic              | Pulmonary fibrosis    | Pulmonary function test (PFT), yearly. |
| Hematology Clinic             | Bone marrow failure   | Complete blood count (CBC), yearly |
| Dermatology Clinic            | Skin hyperpigmentation, nail dystrophy, oral leukoplakia | Full Body Skin Examination, yearly. |
Early diagnosis of DC is advantageous in that it enables harvesting and storage of bone marrow before the onset of the BMF [3]. Hematology consultation is recommended for treatment of BMF if the hemoglobin is consistently below 8 g/dL, platelets below 30,000/mm³, and neutrophils below 1000/mm³. If a matched-related donor is available, HSCT should be the first treatment for hematologic complications regardless of age, such as BMF or leukemia [3].

CONCLUSION

Dyskeratosis congenita is a rare condition with a predisposition for malignant progression. This case report describes a young girl with progressive changes of leukoplakia concerning for malignant transformation. Patients must have coordinated care and be closely followed by different specialists and primary care providers.

Author Contributions
Lauren Magnani – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Danilo C. Delcampo – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Final approval of the version to be published
Marian Russo – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2016 Lauren Magnani et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

1. Fernández García MS, Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med 2014 Aug 21;5:157–67.
2. Handley TP, McCaul JA, Ogden GR. Dyskeratosis congenita. Oral Oncol 2006 Apr;42(4):331–6.
3. Savage SA. Dyskeratosis Congenita. 2009. In: Pagon RA, Adam MP, Ardinger HH et al. eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. [Available at: http://www.ncbi.nlm.nih.gov/books/NBK22301/]
4. Abdel-Karim A, Frezzini C, Viggor S, Davidson LE, Thornhill MH, Yeoman CM. Dyskeratosis congenita: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009 Aug;108(2):e20–4.
5. Brown CJ. Dyskeratosis congenita: report of a case. Int J Paediatr Dent 2000 Dec;10(4):328–34.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open-access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.